High-throughput and automation in novel modalities (msAbs, ADCs, AOCs) screening, characterization, and beyond

Novel biotherapeutics, including bispecific and multispecific antibodies (bsAb, msAb), antibody-drug conjugates (ADCs), and antibody-oligonucleotide conjugates (AOCs), are revolutionizing biomedical therapies yet pose analytical challenges due to their sequence diversity, structural complexity, and susceptibility to various degradation pathways.

In this presentation, Ben Niu will showcase how his team has integrated advanced techniques such as automation and machine learning to achieve unprecedented mass spectrometry-focused sample handling capabilities and rapid turnover rates. These approaches deliver unmatched depth and breadth in understanding diverse molecular modalities within a condensed timeline.

Who should attend?

Scientists who develop novel biotherapeutics

What You Will Learn?

Overcoming analytical challenges relating to the development of novel biotherapeutics, via utilization of automation and machine learning to achieve unprecedented mass spectrometry-focused sample handling capabilities and rapid turnover rates.

Presenter: Ben Niu, PhD (Principal Scientist, Discovery Biotherapeutics, Bristol Myers Squibb)

Ben Niu is a Principal Scientist at Bristol Myers Squibb (BMS), leading a pioneering mass spectrometry team within the Discovery Biotherapeutics department. With over seven years of experience in the biopharmaceutical industry, Ben specializes in analytical characterization, particularly in mass spectrometry techniques, driving critical insights for drug development. He champions the integration of automation and machine learning to revolutionize analytical workflows.

Presenter: Dr. Kelly Broster (Sr Manager, Market Development & Collaborations, Pharma Biopharma, Thermo Fisher Scientific)